Hypertension: ReCor Launches Post-Market Study of Next-Gen Paradise System
ReCor Medical enrolls the 1st patients in a post-market study of its ultrasound-based renal denervation therapy in treatment of resistant high blood pressure.

California medical device startup ReCor Medical launched a post-market study of its next-generation Paradise renal denervation system in treatment of patients with resistant high blood pressure.
The 50-patient study has already enrolled patients at a participating facility in the Netherlands with the Paradise device, the only renal denervation device on the European market that treats high blood pressure with ultrasound rather than radiofrequency.